ClinicalTrials.gg
CompletedNCT00822237Updated Apr 12, 2017Results posted

Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)

A Phase 3 interventional study of Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) and Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck) in Varicella, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 12 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
598
Allocation
Randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing Chickenpox Vaccine in Chickenpox — 5 open to participants now, 7 under way, 4 of them phase 3. Chickenpox Vaccine · Chickenpox.

Enrollment
14th of 36
598 · median 404
Started
2009
with 2 others
Phase 3
12 of 36
2 open now
Registered
9th of 36
by date
Lead sponsor
5 of 36
Merck Sharp & Dohme LLC

Among the 36 studies testing Chickenpox Vaccine in Chickenpox, this one is the 14th largest by enrollment, is one of 3 that started in 2009, is one of 12 in phase 3, and was the 9th registered.

Chickenpox

180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.

Browse Chickenpox studies →

Open to participants now

5 of the 36 studies testing Chickenpox Vaccine in Chickenpox are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About Chickenpox Vaccine

Chickenpox Vaccine: first FDA approval 1995 (Varivax). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Chickenpox studies recruiting now, 3 (19%) set no upper age limit and 13 (81%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing Chickenpox Vaccine in Chickenpox, or all of them as a file.
02

Study summary

This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly administered with M-M-R II in healthy children.

Read the detailed description

This treatment has been approved for sale to the public.

03

Conditions studied

  • Varicella

Browse trials for

04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is in good health based on medical history
  • Subject has no history of measles, mumps, rubella, chickenpox, or shingles

Exclusion criteria

Exclusion Criteria:

  • Subject has previously received measles, mumps, rubella, and/or varicella vaccine either alone or in combination
  • Subject has history of immune disorders
  • Subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella within 4 weeks of study start
  • Subject has received an inactivated vaccine within 14 days of first dose of study vaccine
  • Subject has received a within 30 days of first dose of study vaccine
  • Subject has received a blood transfusion or blood-derived products within 3 months of receiving study vaccine
  • Subject has had a fever within 72 hours of study start
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
598 participants (actual)

Study arms

  • Experimental
    VARIVAX 2007 process + M-M-R II

    Biological: Varicella Virus Vaccine Live (2007 Process) (Oka/Merck) · Biological: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)

  • Active comparator
    VARIVAX 1999 process + M-M-R II

    Biological: Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck) · Biological: Measles, Mumps, and Rubella Virus Vaccine Live (MMR)

Interventions

  • BiologicalVaricella Virus Vaccine Live (2007 Process) (Oka/Merck)

    Drug page: Chickenpox Vaccine

    VARIVAX (2007 process) in two 0.5 mL doses by injection \~6 weeks apart

  • BiologicalComparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)

    Drug page: Chickenpox Vaccine

    VARIVAX (1999 process) in two 0.5 mL doses by injection \~6 weeks apart

  • BiologicalMeasles, Mumps, and Rubella Virus Vaccine Live (MMR)

    M-M-R II in two 0.5 mL doses by injection \~6 weeks apart

06

What researchers measure

Primary outcomes

  1. Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).

    Percent of participants with varicella antibody titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer \< 1.25 gpELISA units/mL. Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.

    Time frame: 6 weeks following first vaccination

07

Results

Posted Apr 21, 2011

Participant flow

Dose 1 Vaccination
Participant flow — Dose 1 Vaccination
MilestoneVARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R II
Started299299
Completed274273
Not completed2526
Withdrew: Not vaccinated30
Withdrew: Withdrawal by subject1314
Withdrew: Lost to follow-up912
Dose 2 Vaccination
Participant flow — Dose 2 Vaccination
MilestoneVARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R II
Started274273
Completed270262
Not completed411
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up29

Outcome measures

PrimaryPercent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).

Percent of participants with varicella antibody titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer \< 1.25 gpELISA units/mL. Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.

Time frame:
6 weeks following first vaccination
Reported as:
Number · Percent of participants
Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).
Percent of participantsVARIVAX 2007 Process + M-M-R II
Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).96.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VARIVAX 2007 Process + M-M-R II—1/296 (0.3%)189/296 (63.9%)
VARIVAX 1999 Process + M-M-R II—1/299 (0.3%)156/299 (52.2%)
Most frequent serious events
Most frequent serious events
EventVARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R II
Croup infectiousInfections and infestations1/2960/299
Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders0/2961/299
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R II
Injection site painGeneral disorders84/29670/299
PyrexiaGeneral disorders74/29665/299
Injection site erythemaGeneral disorders67/29664/299
Injection site swellingGeneral disorders32/29635/299
Otitis mediaInfections and infestations31/29622/299
IrritabilityGeneral disorders27/29615/299
DiarrhoeaGastrointestinal disorders24/29617/299
Dermatitis diaperSkin and subcutaneous tissue disorders21/29615/299
VomitingGastrointestinal disorders20/29613/299
Upper respiratory tract infectionInfections and infestations20/29620/299

Baseline characteristics

Age, Continuous
Age, Continuous(months)VARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R IITotal
Mean13.0 ± 1.8313.0 ± 1.8313.0 ± 1.83
Sex: Female, Male
Sex: Female, Male(Participants)VARIVAX 2007 Process + M-M-R IIVARIVAX 1999 Process + M-M-R IITotal
Female158138296
Male141161302
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Oct 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2009
First posted
Jan 14, 2009
Start
Jan 2009
Primary completionActual
Oct 2009
CompletionActual
Dec 2009
Results first posted
Apr 21, 2011
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00822237
Responsible party
Sponsor
First posted
Jan 14, 2009
Start date
Jan 2009
Primary completion
Oct 2009
Completion
Dec 2009
Results posted
Apr 21, 2011
Last update
Apr 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chickenpox Vaccine

Start the discussion